1. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. (7th March 2020) Authors: Hajek, Roman; Pour, Ludek; Ozcan, Muhit; Martin Sánchez, Jesus; García Sanz, Ramon; Anagnostopoulos, Achilles; Oriol, Albert; Cascavilla, Nicola; Terjung, Andreas; Lee, Yihua; Briso, Eva M.; Dobkowska, Edyta; Hauns, Bernhard; Špička, Ivan Journal: European journal of haematology Issue: Volume 104:Number 5(2020) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Issue 1 (6th June 2012) Authors: Grzasko, Norbert; Hus, Marek; Pluta, Andrzej; Jurczyszyn, Artur; Walter‐Croneck, Adam; Morawska, Marta; Chocholska, Sylwia; Hajek, Roman; Dmoszynska, Anna Journal: Hematological oncology Issue: Volume 31:Issue 1(2013:Mar.) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. (7th July 2015) Authors: Ludwig, Heinz; Greil, Richard; Masszi, Tamas; Spicka, Ivan; Shpilberg, Ofer; Hajek, Roman; Dmoszynska, Anna; Paiva, Bruno; Vidriales, María‐Belén; Esteves, Graca; Stoppa, Anne Marie; Robinson, Don; Chaturvedi, Shalini; Ataman, Ozlem; Enny, Christopher; Feng, Huaibao; van de Velde, Helgi; Viterbo,... Journal: British journal of haematology Issue: Volume 171:Number 3(2015:Nov.) Page Start: 344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Issue 10 (October 2017) Authors: Dimopoulos, Meletios A; Goldschmidt, Hartmut; Niesvizky, Ruben; Joshua, Douglas; Chng, Wee-Joo; Oriol, Albert; Orlowski, Robert Z; Ludwig, Heinz; Facon, Thierry; Hajek, Roman; Weisel, Katja; Hungria, Vania; Minuk, Leonard; Feng, Shibao; Zahlten-Kumeli, Anita; Kimball, Amy S; Moreau, Philippe Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. Issue 10 (30th October 2022) Authors: Sonneveld, Pieter; Zweegman, Sonja; Cavo, Michele; Nasserinejad, Kazem; Broijl, Annemiek; Troia, Rosella; Pour, Ludek; Croockewit, Sandra; Corradini, Paolo; Patriarca, Francesca; Wu, Kalung; Droogendijk, Jolanda; Bos, Gerard; Hajek, Roman; Teresa Petrucci, Maria; Ypma, Paula; Zojer, Nicholas; Min... Journal: HemaSphere Issue: Volume 6:Issue 10(2022) Page Start: e786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Centrosome amplification and clonal evolution in multiple myeloma: Short review. (February 2016) Authors: Kryukova, Elena; Kryukov, Fedor; Hajek, Roman Journal: Critical reviews in oncology/hematology Issue: Volume 98(2016) Page Start: 116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. Issue 1 (December 2016) Authors: Kryukov, Fedor; Nemec, Pavel; Radova, Lenka; Kryukova, Elena; Okubote, Samuel; Minarik, Jiri; Stefanikova, Zdena; Pour, Ludek; Hajek, Roman Journal: Journal of translational medicine Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Issue 16 (December 2015) Authors: Gay, Francesca; Oliva, Stefania; Petrucci, Maria Teresa; Conticello, Concetta; Catalano, Lucio; Corradini, Paolo; Siniscalchi, Agostina; Magarotto, Valeria; Pour, Luděk; Carella, Angelo; Malfitano, Alessandra; Petrò, Daniela; Evangelista, Andrea; Spada, Stefano; Pescosta, Norbert; Omedè, Paola; C... Journal: Lancet oncology Issue: Volume 16:Issue 16(2015) Page Start: 1617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗